AIM ImmunoTech Inc.

AIM

US00901B1052

Biotechnology & Medical Research

Delayed Nyse Other stock markets 17:44:00 02/07/2024 BST			5-day change	1st Jan Change
0.37 ^USD	-0.99%		-2.61%	-15.89%

06-05	Transcript : AIM ImmunoTech Inc. - Special Call
05-16	Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024

Hemispherx Biopharma, Inc. Announces Resignation of Iraj Kiani as Member of the Board of Directors

June 20, 2016 at 09:16 pm

Hemispherx Biopharma, Inc. announced that on June 16, 2016, Iraj Kiani has resigned as a member of the Board of Directors.

Latest news about AIM ImmunoTech Inc.

Transcript : AIM ImmunoTech Inc. - Special Call	06-05
Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024	05-16
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	04-29	MT
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	04-10	CI
Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024	04-02
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Transcript : AIM ImmunoTech Inc. - Special Call	03-20
AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding	02-19	CI
AIM ImmunoTech Inc. announced that it has received $2.5 million in funding	02-15	CI
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	02-08	CI
AIM ImmunoTech Says First Subject Enrolled in Phase 1b/2 Study of Pancreatic Cancer Combination Therapy	01-22	MT
Declaration of Voting Results by AIM ImmunoTech	01-10	CI
Transcript : AIM ImmunoTech Inc. - Pre Recorded Special Call	01-09
Kellner Group Issues a Statement to the Shareholders	01-03	CI
Sector Update: Health Care	12-29	MT
AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	12-29	MT
Sector Update: Health Care Stocks Advance Late Afternoon	12-29	MT
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board?s Determination that Activist Group?s Nominations Are Invalid	12-29	CI
AIM ImmunoTech Provides Update Regarding Annual Meeting	11-28	CI
AIM ImmunoTech Gets US Patents for Ampligen Cancer, ME/CFS Treatment Methods	11-27	MT
AIM ImmunoTech Treats Last Participant in Phase 2 Study of Ampligen for Potential Treatment of Post-COVID Fatigue	11-21	MT
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	11-21	CI
AIM ImmunoTech Mails Letter to its Shareholders	11-20	CI

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AIM ImmunoTech Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3737 USD

Average target price

3.583 USD

Spread / Average Target

+858.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AIM IMMUNOTECH INC.	-15.89%	21.35M
VERTEX PHARMACEUTICALS INCORPORATED	+16.35%	122B
REGENERON PHARMACEUTICALS, INC.	+17.44%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.85%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-20.29%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+60.55%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.76%	14.1B

Bio Therapeutic Drugs

AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Biotechnology & Medical Research

Hemispherx Biopharma, Inc. Announces Resignation of Iraj Kiani as Member of the Board of Directors

Latest news about AIM ImmunoTech Inc.

Chart AIM ImmunoTech Inc.

Company Profile

Income Statement Evolution

Ratings for AIM ImmunoTech Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs